临床试验/NCT04976855

NCT04976855已完成1 期

A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder

Indivior Inc.3 个研究点分布在 1 个国家目标入组 64 人开始时间: 2022年8月17日最近更新: 2024年8月21日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Indivior Inc.
入组人数: 64
试验地点: 3
主要终点: Part I and Part II: Number of Participants With Adverse Events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary objectives for the study are:

Part I and Part II: Assess safety and tolerability of repeated doses of INDV-2000 in healthy volunteers.
Part III: Assess the safety and tolerability of repeated doses of INDV-2000 administered alone and with SUBOXONE sublingual (SL) film in an opioid use disorder (OUD) treatment seeking population.

详细描述

The study will be conducted in 3 parts:

Part I: Double-blind, placebo-controlled, randomized, multiple ascending dose study for 7 days of dosing with INDV-2000 in healthy volunteers.

Part II: Double-blind, placebo-controlled, randomized, multiple ascending dose study for 28 days of dosing with INDV-2000 in healthy volunteers.

Part III: This part is an open-label study in OUD treatment seeking individuals.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Sequential
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Able to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures, be able to comply with protocol requirements, rules and regulations of study site, and be likely to complete all the study interventions.
•Female subjects of child-bearing potential who are sexually active with males must use, with their partner, a condom plus an approved method of effective contraception from the time of screening until 30 days after the last dose of Investigational Medicinal Product (IMP). The impact of IMP on the efficacy of hormonal contraceptives is unknown. Male subjects who are sexually active with female partners of child-bearing potential must use, with their partner, a condom plus an approved method of effective contraception from the time of screening until 90 days after the last dose of IMP and agree to not donate sperm over this time period. Effective methods of contraception are:
•Combined (estrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
•Progestogen-only hormonal contraception: oral, injectable/implantable, or intrauterine hormone-releasing system (IUD)
•Implantable intrauterine device (IUS)
•Surgical sterilization (for example, vasectomy or bilateral tubal ligation)
•Male condom with spermicidal gel/foam or with female cap or diaphragm (double barrier)
•abstinence from heterosexual intercourse as a conscious choice and established pattern of lifestyle
•Part I and II only:
•Healthy male or female.
•Between 18 and 55 years of age inclusive.
•Body mass index (BMI) within 18.0 to 32.0 kg/m^2, inclusive (minimum weight of at least 50.0 kg at Screening).
•Part III only:
•Male or female seeking treatment for OUD with a diagnosis of moderate or severe OUD by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria.
•Between 18 and 65 years of age inclusive.
•BMI within 18.0 to 35.0 kg/m^2, inclusive (minimum weight of at least 50.0 kg at Screening).

排除标准

•Have a medical history of clinically significant neurological, cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder as judged by an Investigator.
•Have clinically significant abnormal biochemistry, hematology or urinalysis results as judged by an Investigator or medically responsible physician.
•Have a history of narcolepsy or other significant sleep disorders.
•Have disorders that may interfere with drug absorption, distribution, metabolism and excretion (ADME) processes.
•Positive test results for human immunodeficiency virus (HIV)-1/HIV-2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb).
•Serious cardiac illness or other cardiac assessments including, but not limited to:
•Uncontrolled arrhythmias.
•History of congestive heart failure (CHF).
•Myocardial infarction <6 months from receipt of first dose of IMP
•Uncontrolled symptomatic angina
•QTcF > 450 msec for males and > 470 msec for females or history of prolonged QT syndrome.
•Current active hepatic or biliary disease, including subjects with cholecystectomy <90 days prior to Screening.
•Concurrent treatment or treatment with an investigational drug within 30 days prior to the first dose of any study drug.
•History of suicidal ideation within 30 days prior to providing written informed consent as evidenced by answering "yes' to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) completed at the Screening Visit or history of a suicide attempt (per the C-SSRS) in the 6 months prior to informed consent.
•Pregnant or lactating females.
•Any consumption of food or drink containing poppy seeds, grapefruit or Seville oranges within 7 days prior to the IMP administration.
•Treatment with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) 3A4 within 30 days prior to first dose of IMP.
•Known allergy or hypersensitivity to IMP or its excipients.
•Any condition that, in the opinion of an Investigator or medically responsible physician, would interfere with evaluation of the IMP or interpretation of subject safety or study results.
•Affiliated with, or a family member of, site staff directly involved in the study, or anyone with a financial interest in the outcome of the study.
•Subjects who are unable, in the opinion of an Investigator or medically responsible physician, to comply fully with the study requirements.
•Participation in any other clinical study within 30 days prior to signing the informed consent form.
•Current incarceration or pending incarceration/legal action that could prevent participation or compliance in the study.
•Part I and II only:
•Regular alcohol consumption in males > 21 units per week and females > 14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).
•Positive test result for alcohol and/or any drugs of abuse at screening
•Have a blood pressure reading outside of the following range: Systolic < 86 or > 149 mmHg; Diastolic < 50 or > 94 mmHg
•Current smokers and those who have smoked within the last 90 days. Current users of e-cigarettes and nicotine replacement products, and those who have used these products within the last 90 days.
•Blood donation of greater than 500 mL within 56 days or plasma donation within 7 days of screening; clinically significant anemia or low hemoglobin (<11 g/dL for females, <12 g/dL for males).
•Healthy volunteers who are taking, or have taken, any prescribed or over-the-counter drugs (other than 2 g per day acetaminophen, hormone replacement therapy [HRT], hormonal contraception) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis if considered not to interfere with the objectives of the study, as agreed by an Investigator and Sponsor's Medical Monitor.
•Part III only:
•Regular alcohol consumption in males > 27 units per week and females > 20 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).
•Current substance use disorder, as defined by DSM-5 criteria, with any substances other than opioids, tobacco, cannabis, or alcohol, or dependence with any substance that would interfere with the completion of the study by judgment of the Investigator or medically responsible physician.
•Current history of alcohol withdrawal within one year prior to screening.
•Blood donation of greater than 500 mL within 56 days or plasma donation within 7 days of screening; clinically significant anemia or low hemoglobin (< 10 g/dL for females, < 12 g/dL for males).
•Have a blood pressure reading outside of the following range: Systolic < 86 or > 159 mmHg; Diastolic < 50 or > 99 mmHg. Investigator should rule out acute changes resulting from opioid withdrawal.
•Has total bilirubin ≥ 1.5 × upper limit of normal (ULN) (with direct bilirubin > 1.3 mg/dL), alanine aminotransferase (ALT) ≥ 3 × ULN, aspartate aminotransferase (AST) ≥ 3 × ULN, serum creatinine > 2 × ULN, or international normalized ratio (INR) > 1.5 × ULN at Screening).
•Received medication-assisted treatment for OUD (e.g., methadone, buprenorphine) in the 30 days prior to providing written informed consent.
•Received any prior treatment with a buprenorphine implant or injection.
•Treatment for OUD required by court order.

研究组 & 干预措施

Part I Cohort 1 INDV-2000 100 mg QD

Experimental

Healthy volunteers will receive INDV-2000 100 mg once daily for 7 days.

干预措施: INDV-2000 (Drug)

Part I Cohort 1 Placebo

Placebo Comparator

Healthy volunteers will receive placebo once daily for 7 days.

干预措施: Placebo (Drug)

Part I Cohort 2 INDV-2000 100 mg BID

Experimental

Healthy volunteers will receive INDV-2000 100 mg twice daily for 7 days.

干预措施: INDV-2000 (Drug)

Part I Cohort 2 Placebo

Placebo Comparator

Healthy volunteers will receive placebo twice daily for 7 days.

干预措施: Placebo (Drug)

Part II Cohort 1 INDV-2000 200 mg BID

Experimental

Healthy volunteers will receive INDV-2000 200 mg twice daily for 28 days.

干预措施: INDV-2000 (Drug)

Part II Cohort 1 Placebo

Placebo Comparator

Healthy volunteers will receive placebo twice daily for 28 days.

干预措施: Placebo (Drug)

Part II Cohort 2 INDV-2000 400 mg BID

Experimental

Healthy volunteers will receive INDV-2000 400 mg twice daily for 28 days.

干预措施: INDV-2000 (Drug)

Part II Cohort 2 Placebo

Placebo Comparator

Healthy volunteers will receive placebo twice daily for 28 days.

干预措施: Placebo (Drug)

Part III INDV-2000 400 mg BID + SUBOXONE SL Film

Experimental

Participants with opioid use disorder will receive SUBOXONE sublingual (SL) film for 6 days during the run-in period. Participants will then receive SUBOXONE SL film alone for 2 days, then SUBOXONE SL film and INDV-2000 for 7 days followed by INDV-2000 dosing alone for 4 days.

干预措施: INDV-2000 (Drug)

Part III INDV-2000 400 mg BID + SUBOXONE SL Film

Experimental

干预措施: SUBOXONE® sublingual film (Drug)

结局指标

主要结局

Part I and Part II: Number of Participants With Adverse Events

时间窗: From first dose of study drug up to 7 days after last dose (up to 14 days in Part I and 35 days in Part II).

Part III: Number of Participants With Adverse Events

时间窗: From first dose of INDV-2000 up to 7 days after last dose (up to 18 days).

次要结局

Part I and Part II: Maximum Plasma Concentration (Cmax) of INDV-2000 Following Dosing on Days 1 and 7 for Part I and Days 1, 7, and 28 for Part II(Days 1 and 7 for Part I and Days 1, 7, and 28 for Part II, predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose)
Part I and Part II: Time to Maximum Plasma Concentration (Tmax) of INDV-2000 Following Dosing on Days 1 and 7 for Part I and Days 1, 7, and 28 for Part II(Days 1 and 7 for Part I and Days 1, 7, and 28 for Part II, predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose)
Part I and Part II: Area Under the Plasma Concentration-time Curve (AUC0-τ) of INDV-2000 Following Dosing on Days 1 and 7 for Part I and Days 1, 7, and 28 for Part II(Days 1 and 7 for Part I and Days 1, 7, and 28 for Part II, predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose)

研究者

发起方

Indivior Inc.

申办方类型

Industry

责任方

Sponsor

研究点 (3)

Loading locations...

相似试验

已完成

不适用

Double-Blind Study of Topical WBI-1001 Cream on Patients With PsoriasisPsoriasis

NCT00830817Welichem Biotech Inc.36

已完成

1 期

A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16Healthy Volunteers and Asthma

NCT01704040Janssen Research & Development, LLC76

已完成

1 期

Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy SubjectsKidney Transplantation

NCT05948059Guangdong Hengrui Pharmaceutical Co., Ltd52

已完成

1 期

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's ColitisInflammatory Bowel DiseasesUlcerative ColitisCrohn Disease

NCT02330653Stacy A. Kahn15

已完成

1 期

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in JapaneseHealthy Subjects

NCT00818129AstraZeneca62